Abstract
IntroductionThis study aims to evaluate effect of 4-factor PCC on outcomes of severe TBI patients on preinjury anticoagulants undergoing craniotomy/craniectomy. MethodsIn this analysis of 2018–2020 ACS-TQIP, patients with isolated blunt severe TBI (Head-AIS≥3, nonhead-AIS<2) using preinjury anticoagulants who underwent craniotomy/craniectomy were identified and stratified into PCC and No-PCC groups. Outcomes were time to surgery and mortality. Multivariable binary logistic and linear regression analyses were performed. Results1598 patients were identified (PCC-107[7 %], No-PCC-1491[93 %]). Mean age was 74(11) years, 65 % were male, median head AIS was 4. Median time to PCC administration was 109 min. On univariable analysis, PCC group had shorter time to surgery (PCC-341, No-PCC-620 min, p = 0.002), but higher mortality (PCC35 %, No-PCC21 %,p = 0.001). On regression analysis, PCC was independently associated with shorter time to surgery (β = −1934,95 %CI = −3339to-26), but not mortality (aOR = 0.70,95 %CI = 0.14–3.62). ConclusionPCC may be a safe adjunct for urgent reversal of coagulopathy in TBI patients using preinjury anticoagulants.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.